Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Advances study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://carlm630pfu8.mdkblog.com/profile